Sutro Biopharma (STRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sutro Biopharma (STRO) has a cash flow conversion efficiency ratio of 0.438x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.19 Million) by net assets ($-87.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Sutro Biopharma to measure how many days the company can operate on defensive assets alone.
Sutro Biopharma - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sutro Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sutro Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sutro Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Western Energy Services Corp.
TO:WRG
|
0.027x |
|
Industri Dan Perdagangan Bintraco Dharma Tbk PT
JK:CARS
|
0.014x |
|
Anfield Energy Inc.
NASDAQ:AEC
|
-0.070x |
|
Wintao Communications Co. Ltd
SHE:301139
|
0.002x |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
0.017x |
|
GIIR Inc
KO:035000
|
0.007x |
|
SAMYOUNG M-Tek Co. Ltd
KQ:054540
|
-0.010x |
|
Cartier Resources Inc
V:ECR
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Sutro Biopharma (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sutro Biopharma from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see STRO company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $44.60 Million | $-191.54 Million | -4.295x | -475.79% |
| 2023-12-31 | $149.65 Million | $-111.62 Million | -0.746x | -4661.44% |
| 2022-12-31 | $217.05 Million | $3.55 Million | 0.016x | +105.06% |
| 2021-12-31 | $252.56 Million | $-81.68 Million | -0.323x | -58.38% |
| 2020-12-31 | $332.05 Million | $-67.80 Million | -0.204x | +69.29% |
| 2019-12-31 | $97.79 Million | $-65.02 Million | -0.665x | -789.62% |
| 2018-12-31 | $131.54 Million | $12.68 Million | 0.096x | -71.65% |
| 2017-12-31 | $-109.00 Million | $-37.07 Million | 0.340x | +135.06% |
| 2016-12-31 | $-90.90 Million | $-13.15 Million | 0.145x | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more